Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by FWG Holdings LLC

FWG Holdings LLC increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,715 shares of the medical equipment provider’s stock after acquiring an additional 124 shares during the quarter. FWG Holdings LLC’s holdings in Zimmer Biomet were worth $402,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC increased its stake in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the third quarter valued at $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet during the 3rd quarter valued at $35,000. Finally, Kentucky Trust Co acquired a new position in Zimmer Biomet during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 2.4 %

Shares of ZBH opened at $107.87 on Monday. The stock’s 50-day moving average price is $105.55 and its 200 day moving average price is $107.15. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The firm has a market capitalization of $21.47 billion, a price-to-earnings ratio of 24.24, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZBH. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Truist Financial reiterated a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Finally, Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.